{"name":"Spanish Lung Cancer Group","slug":"spanish-lung-cancer-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Docetaxel/Cisplatin control","genericName":"Docetaxel/Cisplatin control","slug":"docetaxel-cisplatin-control","indication":"Non-small cell lung cancer (NSCLC), advanced or metastatic","status":"phase_3"}]}],"pipeline":[{"name":"Docetaxel/Cisplatin control","genericName":"Docetaxel/Cisplatin control","slug":"docetaxel-cisplatin-control","phase":"phase_3","mechanism":"This combination uses docetaxel (a microtubule-stabilizing taxane) and cisplatin (a platinum-based DNA-damaging agent) to inhibit cell division and induce apoptosis in lung cancer cells.","indications":["Non-small cell lung cancer (NSCLC), advanced or metastatic"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-09","type":"pipeline","source":"EL PAÍS English","summary":"The true story behind Mariano Barbacid’s ‘first effective therapy against pancreatic cancer’ - EL PAÍS English","headline":"The true story behind Mariano Barbacid’s ‘first effective therapy against pancreatic cancer’ - EL PAÍS English","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XTVdVbGl6cFVVbWNvaFIwbnJWd2NYemVkSUV3SGI0NFcweXplS3paSDFwV3YwUXhOWW5KTG5BaFZBN1pMc3VQaWt1TVN5OFZFQkZnZ0xnWmZyWXVjVFlr?oc=5","date":"2025-12-23","type":"trial","source":"Nature","summary":"Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial - Nature","headline":"Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNWWxXbGh1TTRMcVVEaFNXYVlqSm1MNGFsRl90NkMyZG95WDRkb3ZPNUx0LUIxVUJaaXRSWk9SaVZLZllwREFsTVdFRjBVTnpuRlJjeDJpS3pTS19USm54SkZCbzJCX3VfejkwODE5dkE1R1NRd0tSaGZFSjdyOGlwVk5KQ3M4ZEV5ZGxHUjdVTnh0aHM4OVdYWGpwaVMtN0Q0TWJGaXFpcXFrdU94YVB0TDNpMjUtZ29qampvTU1vaXQxWmh6WWZMR2E1c2thYzJaLUhXWGN0a2dodFp1UEE?oc=5","date":"2025-10-21","type":"trial","source":"Centro Nacional de Investigaciones Oncológicas - CNIO","summary":"New drug in trial for the main oncogene in pancreatic cancer: one small step for patients, one giant leap for research - Centro Nacional de Investigaciones Oncológicas - CNIO","headline":"New drug in trial for the main oncogene in pancreatic cancer: one small step for patients, one giant leap for research -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA3UjkwekNBY1RiaXZldjdMVDNzUUVIaE1qRW9OSXRwbGlDcU5QVFdMX1dFTDhZazN4STd6RW1qa0dKV19wZGlSdmU3dFp1NW52WFVaRnp5dUxCOUFudU5sSkhxcGJTbmpvcFVROXh3?oc=5","date":"2025-09-11","type":"pipeline","source":"KED Global","summary":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate - KED Global","headline":"J Ints Bio unveils 4th-generation targeted anti-cancer drug candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNaW9rT2dha3o4aGtXSlJnTDZXVXdPaEprU1l6dHNsSGpBTzBmWXJsam5IVm1kZzU4VkZURDcxVkFpT3JDek84RXdXdV9mTHpKd2s0dGRoWWV6djNBUEw4MEJRb2hDSW5teUhtOU5LVFFaVjRKVVVCbVlTR2pVMWlrT2c3b1JiRzBhODY5TzhYMm9VdW01YmxPWEh5UFRnYVJlaWhWZWw4NmVWaHhDMWJON3lWQVpXMzFGWlVtaQ?oc=5","date":"2025-09-11","type":"pipeline","source":"Oncology News Central","summary":"Zidesamtinib Shows Early Signs of Efficacy, Durability in Pretreated ROS1-Positive NSCLC - Oncology News Central","headline":"Zidesamtinib Shows Early Signs of Efficacy, Durability in Pretreated ROS1-Positive NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPdXFxRVNOZ0U1Q3VFX3RTQmNNVjg0WGF2REFVQVNVYVdzV1hyNGFka1R2MFNvMVlRbmhvdmxCWHJIblY0Z185ODJ3ZElSdjhPWHhZSDV4SWRRMThIb1Bob1RGLV9xRFE5OWhlbW9oSS1uRnBqTlZZOGpzT0VidkZVUnpYRVZ2TEVtQ002MFc3VXJIVVR6RllUNnBBbEczbE1jUTdzb0xQSEFXWDVrYkE5WWFhOUlETHZmdmE1ZjA1WmppdFRkc2c4?oc=5","date":"2025-09-10","type":"pipeline","source":"Oncology News Central","summary":"Adjuvant Chemoimmunotherapy May Offer Superior Disease-Free Survival in Resected NSCLC - Oncology News Central","headline":"Adjuvant Chemoimmunotherapy May Offer Superior Disease-Free Survival in Resected NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBPeHBXWDdDY2F0MGFvOXg3b2ZhN2UtQzl4U1NDSFROYXBtU2NiekJGZVJ5ay1kRFM4ZjhGeDVFWmZ2TGtHM25qaE1ucjh5aG1hTTBQVXprNG5IRlhMdWYxWHFRbFp1bERvYmRwVklHZzc3d3JlQVYxbA?oc=5","date":"2025-09-08","type":"trial","source":"pharmaphorum","summary":"Mixed data from lung cancer trials on show at WCLC - pharmaphorum","headline":"Mixed data from lung cancer trials on show at WCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPT3N2cEVPNlpvUEtRbjc3WXRuNlBlRWU3T2NwYUJycl9NX3IzekJxR3ZWdVNCZ2pFbU4yZmtIRExzLV95aXlKaXN5MFhJaC0xMW5QX045YXhNX2pkNTFmeTVOTU9RZ3M2Nk1iMFFLa1V4SmZjQlprSm1uU2pON1JIaVlvd2puOFR6OTlnYWxQSFFiVXpIVWZTcjd3dm1JVElzY3VVLTRtTlZiUlBkUFZ3emNGdnhqd2FGU0FN?oc=5","date":"2025-09-07","type":"pipeline","source":"Fierce Pharma","summary":"AstraZeneca escalates EGFR lung cancer rivalry with J&J as Tagrisso combo posts survival win - Fierce Pharma","headline":"AstraZeneca escalates EGFR lung cancer rivalry with J&J as Tagrisso combo posts survival win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1qY0F2OXdFT1BaWkYtRFRnamdaNkpWZ0FFYXRZdzQxU0tSTnJKWkplU1NkX29hTEFQQWJPY0VVV2hheWUyVVF4VXNHZ0VHWlJJQzAzc2RCMTRDOUJlZHF0MXEwTWRQUFpheVNwSmlhcw?oc=5","date":"2025-08-19","type":"pipeline","source":"Labiotech.eu","summary":"Meet 10 biotech companies you can’t miss in Spain in 2025 - Labiotech.eu","headline":"Meet 10 biotech companies you can’t miss in Spain in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOYmRDdWViRzFLVzhXT0lsRWEtN3hqLUdZUzBIaUJBdWprRGhQQS1yZjY1R2FsYXlKNkxISWxWSUg4ZnlUelhYbnNreXhmWEl2TmNVU3hlQWFyYUZpTmwzSW5OTzE0cWdzaF9GWTBjclItVzZqMzByRDlObC1lWDRPc2x2Tkx4aWVuZk45RnlkdFZsMWZodkNjamgxc25fQ3pVUE5B?oc=5","date":"2025-07-14","type":"regulatory","source":"Yicai Global","summary":"China’s Dizal Pharma Gets US Fast-Track Approval for Lung Cancer Drug - Yicai Global","headline":"China’s Dizal Pharma Gets US Fast-Track Approval for Lung Cancer Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNb1hXYmxRQVFfRWJBNUU5N2tSNDNuSy1Pc3dEMU90Rlp3cWhMYm5tUEg5SWt3RFhScUp2WjN1QVNqYThEbWNjRm45WF9DUW1ySjRIbmM0N2hoU19Ba2hMTlh6RHFXS2RQMFN3cHhRU1p6ZWJ1TkNQYk9GT1JRaFR4ckNybXVGdTljdmc5YWFn?oc=5","date":"2025-03-30","type":"trial","source":"Frontiers","summary":"Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain - Frontiers","headline":"Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFA3NGR1emRhdEZ3a011czZfaGpkRmJuU0o4QThwcnhxbWJLZ3ZfeWczZjNrZWlrRXVsQUgwQnFsUkVPcUdNNjU4M0UwV3dFVFZ1T1pMS0xkcGpBNHpaTmVqbA?oc=5","date":"2023-10-20","type":"pipeline","source":"NEJM","summary":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer - NEJM","headline":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}